Home » Cancer Types » Ovarian Cancer

Ovarian Cancer

Ovarian cancers include cancers that begin in the epithelial cells that line the fallopian tubes or peritoneum as well as the ovaries, and they are collectively called epithelial ovarian cancers. Other types of ovarian cancer arise in other cells, including germ cell tumors, which start in the cells that make eggs, and stromal cell tumors, which start in supporting tissues. 

General Information About Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer


Read the full article on the National Cancer Institute website.

General Information About Ovarian Germ Cell Tumors


Read the full article on the National Cancer Institute website.

General Information About Ovarian Low Malignant Potential Tumors


Read the full article on the National Cancer Institute website.

If you’re having surgery you will be interested in these articles about the best hospital to attend:
Irish Examiner: Ovarian cancer sufferers 70% less likely to die after ‘aggressive surgery’ at Mater hospital 
Irish Times: Big improvement in ovarian cancer outcomes at Mater hospital with aggressive surgical approach.

Other Treatments

High-grade Serous Ovarian Cancer (HGSOC)

The anti-inflammatory drug Indomethacin increases survival in serous ovarian cancer patients according to this study. It found:
Indomethacin decreased survival of primary HGSOC tumor cells and interestingly, cisplatin resistant ovarian tumor cells…exhibited significantly higher cell death upon Indomethacin treatment.

Glycyrrhetinic acid
This study concluded that Glycyrrhetinic acid causes cell death in ovarian cancer cells by inducing apoptosis.

Beta-blockers (BB)
In conclusion, BB use was associated with better survival outcomes in ovarian cancer in cases of long-term use, in presence of hypertension, in cardiovascular and/or other underlying disease (CCI ≥3), and in older patients.

Beta-Blockers May Prolong Survival in Women With Ovarian Cancer

By The ASCO Post
In a first-of-its-kind study, researchers demonstrated a benefit in overall survival among patients with epithelial ovarian cancer receiving generic beta-blocker heart medications. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers.

Key Points

Personalised vaccines for ovarian cancer extend survival rate

Source: Figo.org
A study into the potential benefits of personalised vaccines to treat ovarian cancer in stage III and IV patients has found they can improve survival rates.

Scientists at the Ludwig Institute for Cancer Research in Switzerland discovered that a new type of vaccine induces novel, potent and clinically effective immune responses in those with recurrent forms of the disease.

The personalised vaccine is created using processed cells from the patient’s own tumour and put straight into the immune cells.

Sufficient quantities can be manufactured easily and the therapy has been found to be well-tolerated without complications in the process of administering it.

Researchers observed that the immune response in those given the vaccines was vigorous and targeted known cancer antigens and neoantigens expressed by the patient’s cancer cells.

Lana Kandalaft, adjunct researcher at Ludwig Lausanne, said: “This is the first time ever that a personalised vaccine made from the contents of whole cancer cells has been shown to produce immune responses against neoantigens.

“We’ve also shown that these immune responses are not just any responses, but the type that kill tumour cells, and that they correlate with better progression-free survival and better overall survival of patients.”

About Cancer

Page updated 2024

Please share this page to help others